Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

358 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Clinical significance of monitoring EGFR mutation in plasma using multiplexed digital PCR in EGFR mutated patients treated with afatinib (West Japan Oncology Group 8114LTR study).
Akamatsu H, Koh Y, Okamoto I, Fujimoto D, Bessho A, Azuma K, Morita S, Yamamoto N, Nakagawa K. Akamatsu H, et al. Among authors: fujimoto d. Lung Cancer. 2019 May;131:128-133. doi: 10.1016/j.lungcan.2019.03.021. Epub 2019 Mar 22. Lung Cancer. 2019. PMID: 31027689 Free article.
Preexisting interstitial lung disease is inversely correlated to tumor epidermal growth factor receptor mutation in patients with lung adenocarcinoma.
Fujimoto D, Tomii K, Otoshi T, Kawamura T, Tamai K, Takeshita J, Tanaka K, Matsumoto T, Monden K, Nagata K, Otsuka K, Nakagawa A, Hata A, Tachikawa R, Otsuka K, Hamakawa H, Katakami N, Takahashi Y, Imai Y. Fujimoto D, et al. Lung Cancer. 2013 May;80(2):159-64. doi: 10.1016/j.lungcan.2013.01.017. Epub 2013 Feb 16. Lung Cancer. 2013. PMID: 23419507
Cytokeratin 19 fragment predicts the efficacy of epidermal growth factor receptor-tyrosine kinase inhibitor in non-small-cell lung cancer harboring EGFR mutation.
Tanaka K, Hata A, Kaji R, Fujita S, Otoshi T, Fujimoto D, Kawamura T, Tamai K, Takeshita J, Matsumoto T, Monden K, Nagata K, Otsuka K, Nakagawa A, Tachikawa R, Otsuka K, Tomii K, Katakami N. Tanaka K, et al. Among authors: fujimoto d. J Thorac Oncol. 2013 Jul;8(7):892-8. doi: 10.1097/JTO.0b013e31828c3929. J Thorac Oncol. 2013. PMID: 23591159 Free article.
Features and prognostic impact of distant metastasis in patients with stage IV lung adenocarcinoma harboring EGFR mutations: importance of bone metastasis.
Fujimoto D, Ueda H, Shimizu R, Kato R, Otoshi T, Kawamura T, Tamai K, Shibata Y, Matsumoto T, Nagata K, Otsuka K, Nakagawa A, Otsuka K, Katakami N, Tomii K. Fujimoto D, et al. Clin Exp Metastasis. 2014 Jun;31(5):543-51. doi: 10.1007/s10585-014-9648-3. Epub 2014 Mar 30. Clin Exp Metastasis. 2014. PMID: 24682604
Randomized Phase III Study Comparing Gefitinib With Erlotinib in Patients With Previously Treated Advanced Lung Adenocarcinoma: WJOG 5108L.
Urata Y, Katakami N, Morita S, Kaji R, Yoshioka H, Seto T, Satouchi M, Iwamoto Y, Kanehara M, Fujimoto D, Ikeda N, Murakami H, Daga H, Oguri T, Goto I, Imamura F, Sugawara S, Saka H, Nogami N, Negoro S, Nakagawa K, Nakanishi Y. Urata Y, et al. Among authors: fujimoto d. J Clin Oncol. 2016 Sep 20;34(27):3248-57. doi: 10.1200/JCO.2015.63.4154. Epub 2016 Mar 28. J Clin Oncol. 2016. PMID: 27022112 Clinical Trial.
Aprepitant for refractory nivolumab-induced pruritus.
Ito J, Fujimoto D, Nakamura A, Nagano T, Uehara K, Imai Y, Tomii K. Ito J, et al. Among authors: fujimoto d. Lung Cancer. 2017 Jul;109:58-61. doi: 10.1016/j.lungcan.2017.04.020. Epub 2017 Apr 27. Lung Cancer. 2017. PMID: 28577951
Early Immune-Related Adverse Events and Association with Outcome in Advanced Non-Small Cell Lung Cancer Patients Treated with Nivolumab: A Prospective Cohort Study.
Teraoka S, Fujimoto D, Morimoto T, Kawachi H, Ito M, Sato Y, Nagata K, Nakagawa A, Otsuka K, Uehara K, Imai Y, Ishida K, Fukuoka J, Tomii K. Teraoka S, et al. Among authors: fujimoto d. J Thorac Oncol. 2017 Dec;12(12):1798-1805. doi: 10.1016/j.jtho.2017.08.022. Epub 2017 Sep 20. J Thorac Oncol. 2017. PMID: 28939128 Free article.
358 results